{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:34:35Z","timestamp":1793331275283,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031135","name":"Swedish-Norwegian Foundation for Equine Research","doi-asserted-by":"publisher","award":["H-19-47-479"],"award-info":[{"award-number":["H-19-47-479"]}],"id":[{"id":"10.13039\/100031135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (CAN) decreases hyperinsulinemia in insulin-dysregulated (ID) horses, but its effects on pancreatic \u03b2-cell responsiveness to glucose are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Compare the effects of 2 CAN dosages (0.6 and 1.2\u00a0mg\/kg) with placebo (PBO) on \u03b2-cell responsiveness to IV glucose in ID horses using a graded glucose infusion (GGI) test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-two privately-owned ID horses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized, multicenter, double-blind, parallel-group, multi-arm, PBO-controlled study. Horses underwent GGI testing before and after 4\u00a0weeks of treatment with PO CAN (0.6 or 1.2\u00a0mg\/kg) or PBO. Indices of \u03b2-cell responsiveness included the slope of insulin vs glucose relationship (\u0394I vs \u0394G) and the ratio of the incremental areas under the curve for insulin and glucose (iAUCINS\/iAUCGLU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Least squares (LS) means \u00b1 SEM \u0394I vs \u0394G values were lower with CAN (0.6 and 1.2\u00a0mg\/kg) than with PBO (P\u00a0\u2264\u00a0.001; 22.0\u00a0\u00b1\u00a03.5 and 21.1\u00a0\u00b1\u00a03.2 mIU\/mmol vs 38.4\u00a0\u00b1\u00a03.3 mIU\/mmol) with no difference between CAN dosages (P\u00a0=\u00a0.96). Geometric LS mean (95% CI) iAUCINS\/iAUCGLU values were lower with CAN (0.6 and 1.2\u00a0mg\/kg) compared with PBO (P\u00a0\u2264\u00a0.001; 19.3 [16.5-22.5] and 16.4 [13.9-19.3] mIU\/mmol vs 33.1 [28.4-38.7] mIU\/mmol).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Canagliflozin decreased \u03b2-cell responsiveness to IV glucose in ID horses, representing a key mechanism underlying the hyperinsulinemia-decreasing effect of SGLT2 treatment in horses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag249","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:34:56Z","timestamp":1791394496000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of canagliflozin treatment on \u03b2-cell responsiveness in insulin-dysregulated horses: a 4-week, multi-arm, double-blind, randomized clinical trial"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-9599","authenticated-orcid":false,"given":"Elin","family":"Svonni","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 756 51 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6124-4015","authenticated-orcid":false,"given":"Sanna","family":"Lind\u00e5se","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 756 51 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-0245","authenticated-orcid":false,"given":"Siv","family":"Hanche-Olsen","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1430 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4432","authenticated-orcid":false,"given":"Ingunn Risnes","family":"Hellings","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1430 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-6961","authenticated-orcid":false,"given":"Constanze","family":"Fintl","sequence":"additional","affiliation":[{"name":"Department of Companion Animal Clinical Sciences, Norwegian University of Life Sciences , 1430 \u00c5s ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-8397","authenticated-orcid":false,"given":"Katarina","family":"Nostell","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 756 51 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-6365","authenticated-orcid":false,"given":"Johan","family":"Br\u00f6jer","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Swedish University of Agricultural Sciences , 756 51 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"2026100713345155000_ref1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.domaniend.2011.05.004","article-title":"The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion\/referral equine hospital","volume":"41","author":"Karikoski","year":"2011","journal-title":"Domest Anim Endocrinol."},{"key":"2026100713345155000_ref2","volume-title":"Equine VetCompass, Guiding Evidence-Based Equine Healthcare","author":"Allen","year":"2020"},{"key":"2026100713345155000_ref3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.tvjl.2007.07.003","article-title":"Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies","volume":"174","author":"Asplin","year":"2007","journal-title":"Vet J."},{"key":"2026100713345155000_ref4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2746\/042516409X475779","article-title":"Equine laminitis: induced by 48 h hyperinsulinaemia in Standardbred horses","volume":"42","author":"Laat","year":"2010","journal-title":"Equine Vet J."},{"key":"2026100713345155000_ref5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/evj.12169","article-title":"Insulin dysregulation","volume":"46","author":"Frank","year":"2014","journal-title":"Equine Vet J."},{"key":"2026100713345155000_ref6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.5455\/OVJ.2022.v12.i4.14","article-title":"Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis","volume":"12","author":"Kellon","year":"2022","journal-title":"Open Vet J."},{"key":"2026100713345155000_ref7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/eve.13738","article-title":"Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series","volume":"35","author":"Sundra","year":"2023","journal-title":"Equine Vet Educ."},{"key":"2026100713345155000_ref8","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1098\/rstb.2005.1762","article-title":"Glucose-sensing mechanisms in pancreatic beta-cells","volume":"360","author":"MacDonald","year":"2005","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"2026100713345155000_ref9","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1152\/ajpendo.1995.268.1.E21","article-title":"Insulin secretion and clearance during low-dose graded glucose infusion","volume":"268","author":"Byrne","year":"1995","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2026100713345155000_ref10","doi-asserted-by":"publisher","first-page":"E865","DOI":"10.1152\/ajpendo.00527.2015","article-title":"Linearity of \u03b2-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series","volume":"310","author":"Shankar","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"2026100713345155000_ref11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/dom.13005","article-title":"Review of methods for measuring \u03b2-cell function: design considerations from the restoring insulin secretion (RISE) consortium","volume":"20","author":"Hannon","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"2026100713345155000_ref12","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/jvim.16906","article-title":"Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: a randomized, placebo-controlled, double-blind, study","volume":"37","author":"Lind\u00e5se","year":"2023","journal-title":"J Vet Intern Med."},{"key":"2026100713345155000_ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203655","article-title":"The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies","volume":"13","author":"Meier","year":"2018","journal-title":"PLoS One"},{"key":"2026100713345155000_ref14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/jvp.13470","article-title":"Sodium-glucose transport protein 2 inhibitor use in the management of insulin dysregulation in ponies and horses","volume":"48","author":"Menzies-Gow","year":"2025","journal-title":"J Vet Pharmacol Ther."},{"key":"2026100713345155000_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2024.106894","article-title":"Short-term clinical and biochemical responses following treatment with dapagliflozin or ertugliflozin in horses with hyperinsulinemia: a retrospective case series","volume":"90","author":"Sundra","year":"2025","journal-title":"Domest Anim Endocrinol."},{"key":"2026100713345155000_ref16","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1071\/AN19491","article-title":"A review of recent developments in the pharmacological prevention and treatment of endocrinopathic laminitis","volume":"60","author":"Laat","year":"2020","journal-title":"Anim Prod Sci."},{"key":"2026100713345155000_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2025.106412","article-title":"Canagliflozin: pharmacokinetics, tolerability and glucose\/insulin effects of supratherapeutic doses in healthy horses","volume":"313","author":"Michanek","year":"2025","journal-title":"Vet J."},{"key":"2026100713345155000_ref18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jvp.13476","article-title":"Pharmacokinetics and alterations in glucose and insulin levels after a single dose of canagliflozin in healthy Icelandic horses","volume":"48","author":"Michanek","year":"2025","journal-title":"J Vet Pharmacol Ther."},{"key":"2026100713345155000_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/jvimsj\/aalag107","article-title":"Efficacy and safety of canagliflozin in insulin dysregulated horses: a 4-week multi-arm, double-blind, randomized, clinical trial.","volume":"40","author":"Br\u00f6jer","year":"2026","journal-title":"J Vet Intern Med"},{"key":"2026100713345155000_ref20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.2042-3306.1983.tb01826.x","article-title":"Relationship between condition score, physical measurements and body fat percentage in mares","volume":"15","author":"Henneke","year":"1983","journal-title":"Equine Vet J."},{"key":"2026100713345155000_ref21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.tvjl.2008.02.029","article-title":"Apparent adiposity assessed by standardised scoring systems and morphometric measurements in horses and ponies","volume":"179","author":"Carter","year":"2009","journal-title":"Vet J."},{"key":"2026100713345155000_ref22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00580-011-1284-6","article-title":"Evaluation of an equine-optimized enzyme-linked immunosorbent assay for serum insulin measurement and stability study of equine serum insulin","volume":"21","author":"\u00d6berg","year":"2012","journal-title":"Comp Clin Pathol."},{"key":"2026100713345155000_ref23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.15232\/S1080-7446(15)30475-7","article-title":"A comparison of methodologies for measuring glucose concentrations in the horse1","volume":"27","author":"Slough","year":"2011","journal-title":"Prof Anim Sci."},{"key":"2026100713345155000_ref24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/eve.13924","article-title":"Oral sugar test responses to ertugliflozin in ten horses with insulin dysregulation","volume":"36","author":"Sundra","year":"2024","journal-title":"Equine Vet Educ."},{"key":"2026100713345155000_ref25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/jvim.14799","article-title":"Relationship between \u03b2-cell response and insulin sensitivity in horses based on the oral sugar test and the euglycemic hyperinsulinemic clamp","volume":"31","author":"Lind\u00e5se","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026100713345155000_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2023.105967","article-title":"Equine metabolic syndrome: role of the enteroinsular axis in the insulin response to oral carbohydrate","volume":"294","author":"Laat","year":"2023","journal-title":"Vet J."},{"key":"2026100713345155000_ref27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jvim.15363","article-title":"Insulin and incretin responses to grazing in insulin-dysregulated and healthy ponies","volume":"33","author":"Fitzgerald","year":"2019","journal-title":"J Vet Intern Med."},{"key":"2026100713345155000_ref28","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.2527\/jas.2014-8736","article-title":"Postprandial glucose, insulin, and glucagon-like peptide-1 responses of different equine breeds adapted to meals containing micronized maize","volume":"93","author":"Bamford","year":"2015","journal-title":"J Anim Sci."},{"key":"2026100713345155000_ref29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/evj.13119","article-title":"Repeatability of the hyperglycaemic clamp for assessment of \u03b2-cell response and insulin sensitivity in horses","volume":"52","author":"Lind\u00e5se","year":"2020","journal-title":"Equine Vet J."},{"key":"2026100713345155000_ref30","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1187-P","article-title":"Effects of SGLT2 inhibitors on insulin secretion and insulin resistance\u2014results from a cross-sectional study","volume":"67","author":"Waseda","journal-title":"Diabetes."},{"key":"2026100713345155000_ref31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EC-20-0082","article-title":"Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use","volume":"9","author":"Goto","year":"2020","journal-title":"Endocr Connect."},{"key":"2026100713345155000_ref32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest."},{"key":"2026100713345155000_ref33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"2026100713345155000_ref34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in Zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O\u2019Brien","year":"2017","journal-title":"Diabetes"},{"key":"2026100713345155000_ref35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jvim.15374","article-title":"Influence of dietary restriction and low-intensity exercise on weight loss and insulin sensitivity in obese equids","volume":"33","author":"Bamford","year":"2019","journal-title":"J Vet Intern Med."},{"key":"2026100713345155000_ref36","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2042-3306.1992.tb02812.x","article-title":"Improved insulin sensitivity in hyperinsulinaemic ponies through physical conditioning and controlled feed intake","volume":"24","author":"Freestone","year":"1992","journal-title":"Equine Vet J."},{"key":"2026100713345155000_ref37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1439-0396.2007.00744.x","article-title":"The effect of weight loss by energy restriction on metabolic profile and glucose tolerance in ponies","volume":"92","author":"Van Weyenberg","year":"2008","journal-title":"J Anim Physiol Anim Nutr."},{"key":"2026100713345155000_ref38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jevs.2019.03.214","article-title":"Effects of diet versus exercise on morphometric measurements, blood hormone concentrations, and Oral sugar test response in obese horses","volume":"78","author":"Moore","year":"2019","journal-title":"J Equine Vet Sci."},{"key":"2026100713345155000_ref39","doi-asserted-by":"publisher","DOI":"10.3390\/ani14050727","article-title":"Effect of exercise conditioning on countering the effects of obesity and insulin resistance in horses-a review","volume":"14","author":"Pratt-Phillips","year":"2024","journal-title":"Animals (Basel)"},{"key":"2026100713345155000_ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"2026100713345155000_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101071","article-title":"SGLT2 is not expressed in pancreatic \u03b1- and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans","volume":"42","author":"Chae","year":"2020","journal-title":"Mol Metab."},{"key":"2026100713345155000_ref42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2337\/db19-0888","article-title":"Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets","volume":"69","author":"Saponaro","year":"2020","journal-title":"Diabetes"},{"key":"2026100713345155000_ref43","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026100713345155000_ref44","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.2337\/db17-0055","article-title":"Inhibition of renal sodium-glucose cotransport with empagliflozin lowers fasting plasma glucose and improves \u03b2-cell function in subjects with impaired fasting glucose","volume":"66","author":"Abdul-Ghani","year":"2017","journal-title":"Diabetes"},{"key":"2026100713345155000_ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2023.1159664","article-title":"Hyperinsulinemia: an early biomarker of metabolic dysfunction","volume":"4","author":"Vaidya","year":"2023","journal-title":"Front Clinical Diabetes Healthc."},{"key":"2026100713345155000_ref46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2337\/dc08-1128","article-title":"Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among US adolescents: National Health and Nutrition Examination Survey 2005\u20132006","volume":"32","author":"Li","year":"2009","journal-title":"Diabetes Care"},{"key":"2026100713345155000_ref47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.23736\/S0391-1977.16.02550-5","article-title":"Effect of dapagliflozin administration on metabolic syndrome, insulin sensitivity, and insulin secretion","volume":"43","author":"Gonz\u00e1lez-Ortiz","year":"2018","journal-title":"Minerva Endocrinol."},{"key":"2026100713345155000_ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1003238","article-title":"Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol."},{"key":"2026100713345155000_ref49","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/dom.13980","article-title":"Association of increased hepatic insulin clearance and change in serum triglycerides or \u03b2-hydroxybutyrate concentration via the sodium\/glucose-cotransporter 2 inhibitor tofogliflozin","volume":"22","author":"Matsubayashi","year":"2020","journal-title":"Diabetes Obes Metab."},{"key":"2026100713345155000_ref50","first-page":"19","article-title":"Insulin and insulin resistance","volume":"26","author":"Wilcox","year":"2005","journal-title":"Clin Biochem Rev."},{"key":"2026100713345155000_ref51","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2527\/jas.2015-9817","article-title":"The effect of oral and intravenous dextrose on C-peptide secretion in ponies1","volume":"94","author":"Laat","year":"2016","journal-title":"J Anim Sci."},{"key":"2026100713345155000_ref52","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/biomedicines9091154","article-title":"Short-term SGLT2 inhibitor administration does not Alter systemic insulin clearance in type 2 diabetes","volume":"9","author":"Sato","year":"2021","journal-title":"Biomedicines"},{"key":"2026100713345155000_ref53","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jcjd.2016.03.007","article-title":"Comparison of second-phase insulin secretion derived from standard and modified low-dose graded glucose infusion tests","volume":"40","author":"Lin","year":"2016","journal-title":"Can J Diabetes."}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/5\/aalag249\/71667349\/aalag249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/5\/aalag249\/71667349\/aalag249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:34:59Z","timestamp":1791394499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag249\/8875978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag249","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"aalag249"}}